Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Angelica Cortez

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2018
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor ModelSharareh Niknam, Hampartsoum B Barsoumian, Jonathan E Schoenhals, et al.
Journal of Nanobiotechnology|October 1, 2024
Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3Yun Hu, Sébastien Paris, Narayan Sahoo, et al.
Journal of Nanobiotechnology|September 19, 2022
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancerYun Hu, Sébastien Paris, Genevieve Bertolet, et al.
Cancer Research|November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by RadiotherapyXiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.
Cancer Immunology Research|January 26, 2023
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung CancerKewen He, Hampartsoum B Barsoumian, Nahum Puebla-Osorio, et al.
Journal for Immunotherapy of Cancer|October 27, 2020
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stromaHampartsoum B Barsoumian, Rishab Ramapriyan, Ahmed I Younes, et al.
Frontiers in Immunology|November 21, 2022
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer modelYun Hu, Sébastien Paris, Genevieve Bertolet, et al.
Frontiers in Oncology|October 24, 2024
Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapyNahum Puebla-Osorio, Natalie Wall Fowlkes, Hampartsoum B Barsoumian, et al.
JCI Insight|June 22, 2023
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejectionYun Hu, Sébastien Paris, Narayan Sahoo, et al.
Nature Communications|October 29, 2014
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppressionLimo Chen, Don L Gibbons, Sangeeta Goswami, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2018
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor ModelSharareh Niknam, Hampartsoum B Barsoumian, Jonathan E Schoenhals, et al.
Journal of Nanobiotechnology|October 1, 2024
Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3Yun Hu, Sébastien Paris, Narayan Sahoo, et al.
Journal of Nanobiotechnology|September 19, 2022
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancerYun Hu, Sébastien Paris, Genevieve Bertolet, et al.
Cancer Research|November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by RadiotherapyXiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.
Cancer Immunology Research|January 26, 2023
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung CancerKewen He, Hampartsoum B Barsoumian, Nahum Puebla-Osorio, et al.
Journal for Immunotherapy of Cancer|October 27, 2020
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stromaHampartsoum B Barsoumian, Rishab Ramapriyan, Ahmed I Younes, et al.
Frontiers in Immunology|November 21, 2022
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer modelYun Hu, Sébastien Paris, Genevieve Bertolet, et al.
Frontiers in Oncology|October 24, 2024
Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapyNahum Puebla-Osorio, Natalie Wall Fowlkes, Hampartsoum B Barsoumian, et al.
JCI Insight|June 22, 2023
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejectionYun Hu, Sébastien Paris, Narayan Sahoo, et al.
Nature Communications|October 29, 2014
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppressionLimo Chen, Don L Gibbons, Sangeeta Goswami, et al.
Pageof 7